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1. Introduction
In 2008 cardiovascular disease accounted for 30% of global mortality (17.3 million 
deaths),  thereby representing  the  worldwide  leading cause of  death1.  This  thesis 
contains three studies about gene expression differences in cardiovascular disease. 
The  cardiovascular  diseases  in  question  are  dissections  of  the  ascending  aorta, 
ascending aortic aneurysms associated with bicuspid aortic valve as well  as atrial  
fibrillation.  The  aim  of  each  study  is  to  contribute  to  the  understanding  of  the 
pathogenesis of the particular disease and give future tools in diagnostics.
1.1 Ascending aortic aneurysms and dissections
An aortic aneurysm is a permanent localized dilatation of the aorta with an at least 
50% increase in diameter2. In a population based cohort study the overall incidence 
of  thoracic  aortic  aneurysm  was  10.4  per  100,000  person-years3.  Thoracic 
aneurysms can occur in the ascending aorta, the aortic arch, the descending aorta or  
extend to the abdominal aorta as thoracabdominal aneurysm. With a frequency of 
60%  the  ascending  aorta  is  most  often  affected4.  While  aortic  aneurysms  are 
generally  a  benign  condition,  they  can,  with  growing  diameter,  give  rise  to 
catastrophic  events  like  acute  aortic  dissection  or  aortic  rupture.  At  an  average 
diameter of 6 cm the probability for dissection or rupture of the ascending aorta rises 
from  6.6%  to  36.2%,  thus  marking  a  point  where  surgical  intervention  seems 
necessary5.
An aortic dissection occurs when a tear in the inner aortic layer (the intima) induces a 
splitting of the subsequent layer (the media) and the creation of a false lumen by the 
blood stream. From here the dissection can propagate in anterograde or retrograde 
direction6, 7. A further re-entrance tear may allow the blood to circulate through the 
false lumen leading to the formation of a double channel aorta with a high probability 
of aortic rupture8, 9.
Thoracic aortic dissections are classified according to the site of the initial tear. After 
Stanford,  dissections  involving  the  ascending  aorta  are  classified  as  type  A 
dissection, whereas dissections not involving the ascending aorta are referred to as 
type B dissection10. Among 464 subjects with acute aortic dissection the mean age 
was 63 years, with a male dominance of 65.3% and a 62.3 percentage of type A 
dissections11. 
Thoracic aortic dissection is a severe cardiovascular event with the urgent need for 
treatment. The overall in-hospital mortality for acute aortic dissection is 27.4%, with a 
mortality of 32.5% for type A dissections11, 12. The mortality 6 hours after admission is 
22.7 %, rising to 33.3%, 50% and 68.2% after 12, 24 and 48 hours respectively13.
The molecular mechanisms involved in the pathogenesis of thoracic aortic dissection 
are  multifarious  and  generally  any  condition  that  weakens  the  aortic  wall  can 
contribute to the event. One of these conditions is cystic medial necrosis, a histologic 
abnormality commonly found in aneurysms and dissections of the thoracic aorta and 
characterised by the fragmentation of the elastic lamina, the loss of vascular smooth 
muscle cells and the accumulation of basophilic ground substance14.
Aneurysms and dissections of the thoracic aorta are highly associated with hereditary 
influence, and genetic syndromes like Marfan syndrome, Turner syndrome, Ehlers-
Danlos  syndrome or  Loeys-Dietz  syndrome are  major  predisposing  factors9,  15,  16. 
However only 5% of aortic dissection cases are associated with Marfan syndrome 
and even less with other syndromes, which means the vast majority of cases is non-
syndromic17. In a study by Coady and colleagues 19.3% of 135 individuals with non-
syndromic thoracic aortic aneurysms and dissections displayed a familial pattern of  
inheritance, while the rest was sporadic.  Of the familial  cases, 38.5% showed an 
autosomal dominant mode of inheritance, 23.1% displayed an autosomal dominant 
or X-linked mode of inheritance and 26.9% were in agreement with a recessive mode 
of inheritance18. Many forms of thoracic aortic aneurysms and dissections share a 
perturbation of the transforming growth factor  (TGF-) signalling pathway, known to 
play an important role in cellular proliferation, differentiation and extracellular matrix 
production16.  In  Marfan  syndrome  the  Fibrillin  1 gene  is  mutated,  coding  for  an 
extracellular  matrix  component  which  participates  in  the  regulation  of  TGF- 
bioavailability19-21. Other members of this cytokine signalling pathway are mutated in 
Loeys-Dietz syndrome (TGF- receptor 1 or 2) and a syndrome caused by mutations 
in the  Smad 3  gene, coding for a downstream target of TGF-15,  22. Proteins of the 
extracellular matrix or involved in extracellular matrix assembly play a part  in the 
pathogenesis of thoracic aortic aneurysms and dissections, probably regulated by the 
TGF- pathway.  Matrix  metalloproteinases  (MMPs)  and  tissue  inhibitors  of 
metalloproteinase (TIMPs) facilitate remodelling of the extracellular matrix and are 
dysregulated in thoracic aortic aneurysms and dissections23. Mutations in the fibulin 4 
gene result in a phenotype that comprises thoracic aortic aneurysm in human and 
mice24-26.  Fibulin  1  and  Decorin  are  other  extracellular  components  that  are 
dysregulated  in  aortic  dissection  without  Marfan  syndrome27.  Disturbances  in  the 
contractile apparatus also promote the formation of thoracic aortic aneurysms and 
dissections.  Particularly  mutations  the  gene  coding  for  smooth  muscle  -actin 
(ACTA2)  are  made  responsible  for  14%  of  inherited  ascending  thoracic  aortic 
aneurysms and dissections28.  The  myosin  heavy chain  11 gene (MYH11)  on  the 
other  hand,  is  mutated  in  families  which  display  a  phenotype  of  thoracic  aortic  
aneurysms and dissections paired with a patent ductus ateriosus29, 30. 
As a part of this study the expression of the high mobility group AT-hook 2 (HMGA2) 
gene was to be analysed in thoracic aortic dissection tissue and compared to control 
tissue.  The  HMGA2 gene  codes  for  a  DNA  binding  transcription  factor  mainly 
expressed during embryogenesis but reactivated in numerous human tumors31, 32. In 
cancer biology the HMGA2 protein acts as a downstream target to TGF- signalling 
and elicits the transition of epithelial cells to motile mesenchymal cells, a process 
referred  to  as  epithelial  to  mesenchymal  transition (EMT)33.  It  was  therefore 
hypothesised that the abnormal TGF- signalling in thoracic aortic dissections could 
lead to an increase in HMGA2 expression. 
1.2 The bicuspid aortic valve
The bicuspid aortic valve (BAV) is a common congenital cardiac anomaly. It is the 
most frequent malformation of the heart or great vessels with a prevalence of 0.9% to 
2% in the general  population and a strong male predilection34.  In  contrast  to the 
normal tricuspid aortic valve (TAV) it is comprised of two cusps, often of unequal 
size. The larger cusp frequently features a raphe, a fibrous ridge that represents the 
site of congenital fusion of two cusps35. The cusps are attached to the aortic sinuses, 
which are termed after the position of the coronary arteries as left-coronary, right-
coronary  or  non-coronary  sinus.  Accordingly  BAV  are  classified  by  the  spatial  
position of the fused cusps as L-R (fusion between left- and right-coronary sinus), 
R-N (fusion between right- and non-coronary sinus) and N-L (fusion between non- 
and left-coronary sinus) (Figure 1)36, 37.
Figure 1: Different types of BAV. Fusion between the left- and right-coronary sinus (L-R BAV) 
is shown on the left, fusion between the right- and non-coronary sinus (R-N BAV) is shown in 
the middle and fusion between non- and left-coronary sinus (N-L BAV) is pictured on the 
right. The raphe is presented as black line. L: Left-coronary sinus; N: Non-coronary sinus; R: 
Right-coronary sinus (Figure based on figure 3 from reference 38).
These BAV types are not equally distributed. The L-R type is most common with a 
frequency of 74% to 86%, followed by the R-N type with a frequency of 12% to 24% 
and the L-N type which contributes 0.5% to 3% of BAV cases36-39. Fernández et al. 
demonstrated a different developmental origin of the L-R and R-N type BAV in a 
study that compared inbred syrian hamsters and transgenic mice40. 
The BAV gives often rise to an underlying aortic valve disease, such as aortic valve 
stenosis or aortic valve insufficiency. In a necropsy series of 85 BAV cases, 61 (72%) 
suffered from aortic valve stenosis, often accompanied by aortic valvular calcification. 
Eleven of the 85 cases (13%) had aortic valve insufficiency without stenosis and only 
13 of 85 (15%) had a normal functioning BAV without any further disease34.  Two 
larger clinical studies stated a frequency of 51% to 75% for aortic valve stenosis,  
13%  to  38%  for  aortic  insufficiency,  9%  to  10%  for  combined  stenosis  and 
insufficiency  and  1%  for  a  normal  BAV36,  38.  Since  both  of  these  studies  only 
contained  cases  of  aortic  valve  replacement,  the  frequency  of  a  normal  BAV is 
probably underestimated due to the lesser need for surgery in these patients. Other 
diseases commonly associated with the BAV are infective endocarditis as well  as 
aneurysms and dissections of the aortic root and ascending aorta35, 41-44. Dilatations 
and aneurysms of the ascending aorta occur frequently in patients with BAV. Nistri  
and colleagues found an enlargement of the aortic root in 52% of young men with a  
normal BAV43. Likewise aortic dissections, as a consequence of aortic aneurysms, 
are found more commonly in individuals with BAV. Several studies found an increase 
in BAV prevalence among patients with aortic dissection, ranging from 7.5% to 14% 
for dissections of the ascending aorta41, 42, 45. Compared to the BAV prevalence in the 
general population these studies estimated a five- to nine-fold higher occurrence of 
BAV in cases with aortic dissection34,  45, or the other way round, the presence of a 
BAV increases the risk for aortic dissection by the factor nine41. Additionally aortic 
dissection occurred at a younger age in BAV than in TAV patients (54 vs 62 years)42. 
Thus the existence of a BAV can be seen as a severe risk factor for acute aortic 
dissection. Moreover the commonness of BAV combined with the mortality caused by 
accompanying diseases like aortic valve stenosis, aortic valve insufficiency or aortic 
dissection have provoked Ward to the statement: “This condition may be responsible 
for more deaths and morbidity than the combined effects of all other congenital heart 
defects”46.
Despite intensive research on the field, the genetic basis of the BAV is still poorly 
understood. In a work by Huntington et al. 9.1 % of BAV first degree relatives had a  
BAV themselves,  with  a distribution within  the families that  is compatible  with  an 
autosomal dominant pattern of inheritance with reduced penetrance47. A further study 
of 309 probands with BAV and their relatives detected a BAV prevalence of 24% in 
this group and accordingly estimated a heritability of 89%48. Up to date it has not 
been possible to explain the wide spectrum of BAV manifestations with a single gene 
defect, which indicates that the BAV is most likely a complex and heterogeneous 
disease. Mutations in the signalling and transcriptional regulator  NOTCH1 caused 
BAV and severe aortic valve calcification in two families but can also be observed in 
approximately 4% of sporadic cases49, 50. Furthermore the expression of the UFD1L 
gene and the according protein,  playing a role in the cardiac outflow tract during 
embryogenesis, are down-regulated in BAV tissue51. Family based linkage analysis 
has revealed three loci on chromosomes 18q, 5q and 13q responsible for BAV, but 
no gene was identified52, while a computational approach identified SNPs within the 
AXIN1-PDIA2 locus, the endoglin gene and on chromosome 3 using a genome wide 
SNP data set53. 
Data from animal models bestow additional insight into the pathogenesis of BAV. 
Mice  deficient  of  the  nitric  oxide  generating  enzyme  eNOS  demonstrate  a  high 
frequency of R-N type BAV40, 54. Deletion of the zinc finger protein GATA5 results in a 
25% incidence of R-N type BAV in transgenic mice55 and mice with heterozygous 
mutations in the cardiac homeobox gene Nkx2-5 or mice deficient of the homeobox 
gene Hoxa1 develop a BAV as part of several severe cardiac malformations56, 57.
Irrespective of the pathogenesis is the question why the BAV is accompanied by 
aortic aneurysm with such a high frequency. A connection between the presence of a 
BAV and aneurysm formation  has been  suspected  for  long  and today two  main 
theories are wildly discussed58, 59. The first theory focuses on the assumption that the 
genetic defect responsible for the BAV also weakens the aortic wall and therefore 
facilitates  the  occurrence  of  aortic  aneurysm.  There  is  evidence  in  the  fact  that 
dilatated  BAV  aortas  frequently  feature  the  histologic  abnormality  termed  cystic 
medial  necrosis,  which is also found in aortic aneurysm not linked to BAV60.  The 
second  theory  proposes  a  weakening  of  the  aortic  wall  by  laminar  shear  stress 
caused  by  the  diseased  BAV.  This  theory  is  supported  by  the  asymmetrical 
distribution  of  extracellular  matrix  protein  expression  and  smooth  muscle  cell 
apoptosis within the proximal BAV aorta, indicating shear stress induced changes at 
certain sites61, 62.
One aim of this study was to analyse the expression of the eNOS protein in different  
areas of proximal BAV aortas with aortic aneurysm. While eNOS is also linked to the 
pathogenesis of BAV in mice, Aicher et al found a decreased expression in aortic  
tissue of BAV aneurysm63. They suggested that eNOS plays a role in BAV aneurysm 
formation,  since expression and activity  of  the enzyme can be regulated by fluid 
shear stress64,  65. We therefore wanted to verify if the eNOS protein is asymmetric  
expressed at different aortic locations compared to TAV controls. This would indicate 
that the presence of a BAV could alter the laminar shear stress in the proximal aorta  
and influence gene expression.
1.3 Atrial fibrillation
Atrial fibrillation is a form of cardiac arrhythmia where the atrial activity escapes the 
control of the sinoatrial node and is replaced by disorganized rapid excitations66. The 
overall  prevalence of atrial  fibrillation is 0.4% to 0.95% in the general  population, 
5.5% in patients over 55 years with up to 9% or 17.8% at over 80 years or over 85 
years  respectively,  thus  rendering  it  the  most  common  form  of  arrhythmia67-69. 
Additionally  the  prevalence is  estimated to  double  by the  year  2050,  due to  the 
growing population in elderly people68. The fast excitations of the atrium provoke a 
loss of atrial contraction which leads to stasis of the blood in the atria and thereby 
increases the risk of thromboembolic events66. Hence 15% to 25% of stroke can be 
attributed to the arrhythmia with stroke in atrial fibrillation being more severe than 
other forms70, 71. Overall stroke and other cardiovascular events lead to a doubling of 
mortality in atrial fibrillation71, 72. 
Atrial fibrillation is typically triggered by ectopic foci of anomalous electric activity,  
which  can  originate  from  the  pulmonary  veins  or  from  abnormal  activity  of  the 
automatic  nervous  system73-76.  The  ongoing  arrhythmia  can  induce  electrical 
remodelling of the atria through alterations in ion channel functions and structural 
remodelling via increased fibrosis. These mechanisms can create re-entrant circuits 
of  conduction  either  by shortening  of  the  action  potential  duration  and refractory 
period or by causing conduction delay through fibrotic areas75, 77. Normally an ectopic 
action  potential  can not  activate  neighbouring  tissue zones which  are  still  in  the 
refractory period. A re-entrant circuit arises when fibrotic areas of conduction delay 
cause the impulse to propagate through an alternative, longer pathway and hit the 
neighbouring zone just after the refractory period ends, thereby causing a circuit of  
rapid activation. Multiple re-entrant circuits can exist in the atria, causing an irregular 
excitation66, 77, 78. 
Electrical remodelling of the atria during atrial fibrillation can facilitate to sustain the 
arrhythmia.  The cellular  Ca2+  metabolism plays  an important  part  in  this  process, 
since the rapid excitations of the cells lead to an increased and potentially cytotoxic 
Ca2+  uptake79. As a consequence, the activity and expression of the inward L-type 
Ca2+  current ion channel (Ica) is reduced, leading to a decrease in action potential 
duration and refractory period and thereby promoting the appearance of further re-
entrant circuits80-82.
The fact that atrial fibrillation can sustain itself by electrical and structural remodelling 
offers a classification system based on the duration of the arrhythmia. In the 2010 
atrial fibrillation guidelines of the European Society for Cardiology (ESC) episodes of  
48 hours or less are described as paroxysmal atrial  fibrillation, episodes that last 
longer than 7 days or require medical treatment to be terminated are classified as 
persistent  atrial  fibrillation  and  arrhythmias  that  lasted  for  over  one  year  are 
considered to be long-standing persistent.  An arrhythmia is viewed as permanent 
when it has been accepted by the patient and heart rhythm control is not utilized any 
more83.
Atrial fibrillation is an at least in part heritable disease, since parental atrial fibrillation 
vastly  increases the  risk  of  affected offspring84.  Up to  date  three loci,  which  are 
associated  with  the  disease,  have  been  identified  by  genome  wide  association 
studies.  These are located upstream of  the  transcription factor  gene  PITX2,  and 
within  the  transcription  factor  gene  ZFHX3 and  the  potassium  channel  gene 
KCNN385-88. Various other mutations, mainly in genes coding for potassium or sodium 
channels, have been linked to familial forms of atrial fibrillation, but the mutations in 
the genes coding for the gap junction protein connexin 40, the signalling molecule 
atrial natriuretic peptide and a down-regulation of the extracellular matrix component 
fibulin-1 are also related to the disease89-92.
In recent years the importance of micro RNA (miRNA) mediated post-transcriptional 
regulation  in  the  pathogenesis  of  atrial  fibrillation  has  become  aware93.  Several 
miRNAs have been associated with atrial fibrillation, including miRNA 1, which slows 
conduction and depolarizes the cell membrane by targeting the potassium channel 
gene  KCNJ2 and the gene  GJA1,  coding for connexin 4394.  The miRNA 328 has 
been shown to perturb the cellular Ca2+ metabolism by targeting the calcium channel 
genes CACNA1C and CACNB195. 
A further miRNA linked to arrhythmias in mice is miRNA 208a96. Since this miRNA 
has not yet been analysed in human atrial fibrillation, it was aimed to quantify the 
miRNA 208a expression in  left  atrial  appendage tissue of  human atrial  fibrillation 
patients as a part of this study. Samples of paroxysmal, persistent and long-standing 
persistent atrial fibrillation tissue were planed to be used for this study to investigate 
the expression changes during the time course of the ongoing arrhythmia.
2. Materials and methods
2.1 Protein extraction from tissue samples
For  the  extraction  of  the  cytoplasmatic  protein  fraction  from  snap  frozen  tissue 
samples RIPA-buffer (containing 150mM NaCl,  50mM Tris HCl,  0.5% deoxycholic 
acid  and  1%  NP-40)  was  used  as  cell  lysis  buffer.  First  tissue  samples  of 
approximately 100mg were homogenised in 0.5ml RIPA-buffer containing protease 
inhibitor solution (Roche, Mannheim, Germany). The lysate was incubated on ice for 
45min and subsequently centrifuged for 10min at 12000xg and 4°C. The supernatant  
containing the proteins was stored at -20°C.
2.2 Measuring of whole protein concentration
The  whole  protein  concentration  was  determined  using  the  BCA  protein  assay 
(Thermo Scientific, Rockford, USA) according to the manufacturer’s instructions. The 
micro-plate procedure was utilised and all calculations were done in Excel.
2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
The proteins were separated on NuPAGE 10% Bis-Tris gels using the Xcell SureLock 
Mini-cell (both Invitrogen, Darmstadt, Germany). For publication I between 1µg and 
50µg of whole protein lysate were used as starting amount, whereas for publication II  
20µg of protein lysate were used as starting amount.
2.4 Western blot
The proteins were transferred to a nitrocellulose membrane with the Blot module of 
the  Xcell  SureLock  Mini-cell  (Invitrogen,  Darmstadt,  Germany)  for  1h  at  30V. 
Afterwards the membrane was incubated with blocking buffer (5% BSA in TBS-T) at 
4°C over night, washed thrice in TBS-T and then incubated with the primary antibody 
diluted in blocking buffer for 1h. After an additional wash step the membrane was  
treated with alkaline phosphatase conjugated secondary antibody in blocking buffer 
and then washed again and incubated with NBT/BCIP solution (Roche, Mannheim, 
Germany) until bands developed. The intensity of the bands was quantified with the 
imagej software97.
For  publication  I  primary  antibodies  against  HMGA2  (sc-30223)  and  SNAI1  (sc-
28199) (both by Santa Cruz Biotec, Heidelberg, Germany) were used at a dilution of 
1:200, whereas the secondary antibody bovine anti-rabbit  IgG-AP (sc2372, Santa 
Cruz Biotec, Heidelberg, Germany) was applied in a dilution of 1:5000. In publication 
II primary antibodies against eNOS (sc-654), GAPDH (sc-47724) (both by Santa Cruz 
Biotec,  Heidelberg,  Germany)  were  utilised  at  a  dilution  of  1:200  while  ACTB 
(NB600-501,  Novus  Biologicals,  Herford,  Germany)  was  used  at  a  dilution  of 
1:15000. The secondary antibodies used in this publication were bovine anti rabbit 
IgG-AP (same as in  publication  I)  and Goat  Anti-Mouse-AP (G21060,  Invitrogen, 
Darmstadt, Germany) in a dilution of 1:7500.
2.5 Cell culture
The vascular smooth muscle cells (VSMCs) used in publication II originated from the 
human  aortic  tunica  media.  The  cells  were  immortalised  after  transfection  with 
pSV40-dN-plasmid  DNA.  They  were  grown  in  cell  culture  medium  (TC199  with 
Earle’s salts supplemented with 20% fetal bovine serum, 200 U/mL penicillin, 200 
μg/mL streptomycin) at 37°C and 5% CO2 until approximately 80% confluency and 
where then passaged using TrypLE (Invitrogen, Darmstadt, Germany) to detach the 
cells.
Additionally  primary  human  aortic  endothelial  cells  (HAECs)  (Lonza,  Cologne, 
Germany)  were  grown  in  enthodelial  cell  growth  medium-2  (Lonza,  Cologne, 
Germany) and kept at 37°C and 5% CO2. These cells were also passaged at 80% 
confluency using TrypLE.
2.6 Inhibition of nitric oxide synthase activity
The activity of nitric oxide synthases was inhibited with  Nω-Nitro-L-arginine methyl 
ester  hydrochloride  (L-NAME)  (Sigma-Aldrich,  Seelze,  Germany).  The  L-arginine 
analogue L-NAME can act as an unspecific inhibitor of the three nitric oxide synthase 
isoforms (nNOS, eNOS and iNOS)98,  99.  Therefore VSMCs cells and HAECs were 
grown to 90% confluency and afterwards incubated in serum-free medium for 24h. 
The cells were then treated with 1mM L-NAME for 1h after which the cellular proteins  
were extracted.
2.7 Protein extraction from cells
The cells were washed once with ice-cold PBS before 500µl of RIPA-buffer/protease-
inhibitor  solution  were  added  to  a  25cm2 cell  culture  flask  and  the  cells  were 
detached  using  a  cell  scraper.  The  cell  solution  was  afterwards  incubated  on  a 
shaker on ice for 35min and subsequently centrifuged at 14200xg and 4°C for 20min.  
The supernatant containing the cytosolic protein fraction was collected and stored at 
-20°C.
2.8 Proteome profiler array
The  quantity  of  35  apoptosis  related  proteins  was  measured  with  the  Proteome 
Profiler  Array  for  human  apoptosis  (R&D  Systems,  Wiesbaden-Nordenstadt, 
Germany).  For  this  purpose  200µg  of  L-NAME  treated  cytosolic  proteins  were 
analysed  according  to  the  manufacturer’s  instructions.  However  the  protocol  was 
changed  as  an  antibiotin  alkaline  phosphatase  conjugated  secondary  antibody 
(Sigma-aldrich, Munich, Germany) was used for the detection in a 1:10000 dilution 
together with NBT/BCIP Solution (Roche, Mannheim, Germany). The intensity of the 
single protein spots was quantified with the imagej software and normalised to the 
positive control.
2.9 RNA isolation
RNA isolation from tissue samples  was  carried  out  with  the  TRIzol  reagent  (Life 
Technologies,  Darmstadt,  Germany)  according  to  the  protocol.  For  tissue 
homogenisation approximately 100mg of snap frozen tissue were lysed with 1ml of  
TRIzol reagent in a tissue lyser (Qiagen, Hilden, Germany). Concentration and purity 
of the isolated RNA were determined with a BioPhotometer (Eppendorf, Hamburg, 
Germany).
2.10 cDNA synthesis
For synthesis of cDNA from microRNA the TaqMan MicroRNA Reverse Transcription 
Kit  (Applied  Biosystems,  Weiterstadt,  Germany)  was  used  according  to  the 
manufacturer’s  instructions.  The reverse  transcription  primers  for  microRNA 208a 
were from assay ID 000511 and the primers for RNU48 were from assay ID 001006 
(both Applied Biosystems, Weiterstadt, Germany).
2.11 Real-time PCR
The relative quantification of the MicroRNA 208a expression was carried out on an 
Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems, Weiterstadt, 
Germany).  The  snRNA  RNU48  served  as  endogenous  control,  assay  IDs  for 
MicroRNA 208a and RNU48 are the same as in cDNA synthesis and universal PCR 
mater mix (Applied Biosystems, Weiterstadt, Germany) was used. All samples were 
run in triplicates with controls without reverse transcriptase for every sample and no 
template controls for every PCR reaction. The PCR profile contained an initial step of 
2min at 50°C, followed by a 10min denaturation step at 95°C, and 40 cycles of 15sec 
denaturation at 95°C and 1min annealing/elongation at 60°C. The relative amount of  
the microRNA 208a expression was calculated using the CT method100.
2.12 Statistical analysis
The statistical analysis was done in Microsoft Excel (Microsoft, Redmond, USA) with 
the winSTAT add-in (R.Fitch Software, Bad Krozingen, Germany) and SPSS (IBM, 
Armonk,  USA).  Data  are  usually  presented  as  mean  ±  standard  deviation  or  as 
relative percentage. Differences between independent variables were tested with the 
two-sided  Mann-Whitney  U-test  in  all  three  publications,  whereas  the  Wilcoxon 
signed-rank test was used to analyse dependent variables in publication II. Repeated 
measurement two-way ANOVA was used to analyse the differences in the proteome 
profiler  arrays  (publication  II),  which  consisted  of  two  replicates.  The  two-sided 
Fisher’s exact-test was used to compare categorical variables and the association 
between  different  parameters  was  analysed  by  Pearson’s  correlation  coefficient. 
Significant differences were assumed at p < 0.05.
3. Results
3.1 Publication I: Upregulation of the high mobility group AT-hook 2 
gene in acute aortic dissection is potentially associated with 
endothelial-mesenchymal transition
The high mobility group AT-hook 2 (HMGA2) gene encodes for a non-histonic DNA-
binding protein. Members of the HMGA protein family can bind to AT-rich sequences 
in the minor groove of DNA, cause conformational changes of the DNA and thereby 
regulate  transcription  of  other  genes101-103.  They  are  normally  expressed  during 
embryogenesis but not in differentiated adult  cells,  with  reexpression occurring in 
various tumors31, 32, 104. 
Activation of the TGF- pathway can induce HMGA2 expression via Smad-signalling. 
The HMGA2 protein then proceeds to regulate the expression of SNAI1 and TWIST, 
two  genes  required  for  epithelial  to  mesenchymal  transition  (EMT)33,  105,  106. 
Throughout this process, which is critical to embryogenesis but also contributes to 
tumor invasiveness and metastasis, epithelial cells are converted to mesenchymal 
cells107. In fact the ability of HMGA2 to induce EMT has been demonstrated in various 
cancers108, 109. 
Interestingly  many  forms  of  ascending  aortic  aneurysms  and  dissections  have  a 
dysregulation of the TGF- pathway in common, leading to an increase in TGF- 
signalling in most cases16. It is therefore possible that this would provoke a HMGA2 
reexpression in patients suffering from ascending aortic aneurysms or dissections, 
which could in turn elicit a form of EMT. Accordingly the  HMGA2 expression in 26 
cases of ascending aortic aneurysms and 19 cases of type A acute aortic dissection 
was quantified in this study. Furthermore the  in situ protein expression of HMGA2 
and the EMT-markers SNAI1 and Vimentin was analysed by immunohistochemistry 
and  the  expression  of  the  let-7d microRNA,  which  targets  HMGA2,  was  also 
quantified.
The  HMGA2 expression  in  ascending  aortic  aneurysm  was  modest  (8.6±9.7-fold 
expression  of  the  calibrator),  whereas  it  was  high  in  acute  aortic  dissection 
(193.1±272.8). The difference between acute aortic dissection and samples without  
dissection (ascending aortic  aneurysms with  samples from Marfan syndrome and 
control  samples  from  aortic  valve  tissue)  was  highly  significant  (p  =  1.4*10 -7). 
Increased protein amounts of HMGA2, SNAI1 and Vimentin were detected mainly in 
the endothelial cells of the vasa vasorum, although with seven of eleven cases being 
positive in acute aortic dissection for HMGA2 and SNAI1 and ten of nineteen cases 
being positive for Vimentin, compared to two of eleven cases and two of ten cases, 
respectively, the difference between acute aortic dissection and non-dissecting tissue 
was not significant (p = 0.08 for HMGA2 and SNAI1, and p = 0.1 for Vimentin). The 
correlation between the  let-7d expression and the  HMGA2 expression in the same 
patients was poor, indicating that this microRNA does not regulate HMGA2 in acute 
aortic dissection. 
Taken  together  these  results  suggest  an  increased  HMGA2 expression  in  acute 
aortic dissection patients but not in ascending aortic aneurysms or Marfan syndrome.  
This  HMGA2 overexpression  seems  to  trigger  EMT  in  the  endothelial  cells  as 
indicated by the presence of SNAI1 and Vimentin.
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3.2 Publication II: Locally different endothelial nitric oxide synthase  
protein levels in ascending aortic aneurysms of bicuspid and  
tricuspid aortic valve
The presence of a bicuspid aortic valve (BAV) harbours an increased risk for the 
development of aortic aneurysms and dissections41, 43. The pathogenic mechanisms 
behind  this  relationship  are  still  unclear  but  two  theories  exist,  one  favouring  a 
genetic defect, the other increased shear stress on the aortic wall58, 59. In a study by 
Aicher et al. a significantly lower expression of the endothelial nitric oxide synthase 
(eNOS) was found in the aorta of BAV subjects. Furthermore, there was a significant 
correlation between the amount of eNOS protein and the aortic diameter and it was 
concluded that eNOS may play a role in BAV associated aortopathy63.
The eNOS is an enzyme which catalyses the conversion of L-arginin to L-citrullin and 
nitric  oxide  (NO),  a  signalling  molecule  which  regulates  vascular  homeostasis110. 
Activity and expression of the enzyme are controlled by hemodynamic stimulation of 
the endothelial cells through fluid shear stress64, 65, 111, 112. 
This  study focuses on the  assumption  that  irregular  shear  stress  caused  by the 
malformed aortic valve can lead to spatial dysregulation of eNOS within the aorta and 
therefore cause changes in the aortic environment, which in turn could give rise to 
aortic aneurysms. To test this hypothesis the eNOS protein amount was determined 
in four different aortic areas of 14 BAV and 5 TAV aneurysm cases. 
Additionally the protein levels of 35 apoptosis-related proteins were quantified after 
inhibition  of  NO  synthesis,  since  it  is  documented  that  NO  can  exhibit  an  anti-
apoptotic  effect  and  that  apoptosis  of  vascular  smooth  muscle  cells  acts  as  a 
mechanism of aneurysm formation in BAV113-115.
The  eNOS  protein  expression  showed  a  different  spatial  distribution  in  BAV 
associated aneurysms than in TAV aneurysms, with a higher eNOS amount in the 
BAV concavity than in its TAV counterpart but a significantly reduced eNOS level in 
the BAV proximal aorta compared to the TAV proximal aorta. These results suggest 
that eNOS is indeed spatially dysregulated in the BAV aorta, probably due to the 
change in shear stress distribution.
Inhibition  of  NO synthesis  in  vascular  smooth  muscle cells  (VSMCs)  and human 
aortic endothelial cells (HAECs) lead to little differences in the protein expression of  
the  35 apoptosis-related  proteins.  Only the  cytosolic  amount  of  the  pro-apoptotic 
serine protease HTRA2/Omi was significantly increased after NO synthesis inhibition 
in VSMCs (p = 0.038) but Cytochrome c levels in the cytosol of HAECs were also 
higher  after  the  treatment,  albeit  not  significant  (p  =  0.069).  Both  proteins  are 
released from mitochondria into the cytosol during the intrinsic apoptosis pathway116, 
117. These data give further insight into the way NO confers its anti-apoptopic effects.
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3.3 Publication III: MicroRNA 208 in atrial fibrillation
MicroRNAs (miRNA)  are  small  non-coding  RNA of  approximately  22  nucleotides 
length. They are able to regulate the translation of their target mRNA, either by a 
block of translation or by the induction of mRNA degradation118, 119. MiRNA mediated 
control of translation seems to play an important role in the pathogenesis of atrial 
fibrillation93, 120, 121. The cardiac specific miRNA 208a has been previously associated 
with  cardiac  rhythm  disorders  in  mice.  Interestingly  not  only  transgenic 
overexpression but also knock down of miRNA 208a can cause conduction delay and 
arrhythmias in these animals96.  The miRNA is located intronic to the  Myh6  gene, 
which encodes for the fast myosin heavy chain. MiRNA 208a is part of a miRNA 
family with two other members, intronic within the slow myosin genes122, 123. MiRNA 
208a regulates muscle growth and hypertrophy by targeting the mRNAs of thyroid 
hormone–associated protein  1 and  myostatin  and is  also associated with  cardiac 
fibrosis,  which  is  regularly  seen  during  the  course  of  atrial  fibrillation96,  122,  124. 
Additionally it is required for the proper expression of Connexin 40, a cardiac gap  
junction protein linked to the pathogenesis of atrial fibrillation in animal models 96, 125, 
126.
These data suggest a role for miRNA 208a in human atrial fibrillation and therefore 
its  expression  was  quantified  in  left  atrial  appendage  tissue  of  19  patients.  The 
patient collective consisted of 2 patients with paroxysmal atrial fibrillation, 10 patients 
with  persistent  atrial  fibrillation  and  7  patients  with  long-standing  persistent 
arrhythmia. 
The relative miRNA 208a expression was on a medium level in paroxysmal atrial 
fibrillation,  high  in  patients  with  persistent  and low in  patients  with  long-standing 
persistent  arrhythmia.  The  difference  between  persistent  and  long-standing 
persistent  atrial  fibrillation was significant  with  p = 0.02.  These results suggest  a 
change of miRNA 208a expression over the course of the arrhythmia, with a decline 
of the miRNA from persistent to long-standing persistent atrial fibrillation.
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4. Discussion
4.1 HMGA2 overexpression in the dissecting aorta
A significant upregulation of the HMGA2 gene was demonstrated in aortic tissue of 
acute aortic dissection cases as a part of this study. Other cases of cardiovascular  
disease and heart valve control samples featured a much lower expression of the 
gene, albeit some thoracic aortic aneurysm cases displayed an increased  HMGA2 
expression. These results indicate an association between HMGA2 upregulation and 
acute aortic dissection, as the gene is normally not expressed in the healthy aorta of 
human adults127. Additional experiments proved the presence of the HMGA2 protein, 
as well  as the EMT markers SNAI1 and Vimentin in the endothelium of the  vasa 
vasorum but  also in  the  tunica intima,  thereby suggesting  the  transition of  these 
endothelial cells to mesenchymal cells. The ability of HMGA2 to elicit EMT is already 
known from cancer biology. Here  HMGA2 is re-expressed as a reaction to TGF- 
induced Smad-signaling and then facilitates the expression of EMT promoting factors 
like SNAI1, Slug and Twist33, 105, 106. The same process seems to occur in acute aortic 
dissection, particularly since a dysregulation of the TGF- pathway is seen in many 
forms of aortic dissection16. It is noteworthy that it is not really an EMT taking place in 
the  aorta,  since  the  cells  involved  are  not  epithelial  cells,  but  an  Endothelial  to 
Mesenchymal  Transition  (EndMT).  This  form  of  cell  differentiation  is  generally 
assumed  to  be  similar  to  EMT,  including  activation  by  TGF- signalling  and 
upregulation of SNAI1, and is also involved in cancer progression and fibrosis128-130.
Two  possible  conclusions  can  be  drawn  from  the  HMGA2 upregulation  and 
concomitant EndMT in acute aortic dissection tissue. These events either contribute 
to the pathogenesis of the disease or are a direct result of the injury. In the first case 
the EndMT elicited by HMGA2 would cause a weakening of the endothelial  layer  
through the loss of endothelial  cells. This would facilitate the tearing of the aortic 
layers  during dissection.  The HMGA2,  SNAI1 and Vimentin  proteins were  mainly 
detected in the vasa vasorum endothelium and indeed tearing of these vessels can 
cause  intramural  hematoma,  which  are  considered  to  be  a  precursor  of  aortic 
dissection131.  In this case haemorrhage in the aortic  tunica media can lead to the 
dissection without the presence of an intimal tear. Intramural hematoma constitute 10 
to 30% of all acute aortic dissection cases and feature a higher rate of aortic rupture 
than normal dissections due to their location closer to the tunica adventitia132, 133. 
Additional linkage between aortic disease and HMGA2 was discovered in a genome 
wide  association  study  by  Vasan  and  colleagues134.  A  SNP near  the  gene  was 
strongly linked to the aortic diameter, which is in accordance with the association of 
HMGA2 with growth in mice and man135-139. Therefore HMGA2 overexpression in the 
aortic  endothelium  might  lead  to  an  enlargement  of  the  aortic  diameter,  which 
increases the risk for aortic dissection17. This could represent a further aspect in the 
relationship between HMGA2 expression and aortic dissection. As an interesting side 
note  HMGA2 expression is not only induced by TGF- signalling, but HMGA2 can 
also  enhance  TGF- signalling  by  increasing  expression  of  the  TGF- type  II  
receptor (TGFRII), which could lead to circular proliferation of the signal140. 
There are of course some considerations that render an involvement of the HMGA2 
induced EndMT in the pathogenesis of aortic dissection unlikely. While not all aortic  
dissection cases featured a vastly increased HMGA2 expression, the frequency was 
certainly above 10 to 30 %. Therefore the presence of intramural hematoma can not 
be the reason for dissection in the majority of cases, especially since patients with  
intramural hematoma are reported to be in their mid-seventies on average, while the 
patients in this study featured a mean age of 59.6 years141. Of course HMGA2 and 
the EMT markers were also detected in the tunica intima, a factor that could lead to a 
standard type A dissection by weakening the aortic endothelium. Another aspect that 
makes the  participation of  HMGA2 upregulation  in  aortic  dissection  pathogenesis 
seem dubious, is the fact that aortic dissections are considered to evolve from aortic 
aneurysms. One would expect an increased  HMGA2 expression in these patients, 
contributing to the weakening of the aortic wall and finally leading to the dissection. 
Actually aortic aneurysm cases in this study did feature a slightly higher  HMGA2 
expression  than  other  non-dissecting  tissues,  although  the  difference  was  not 
significant. There was some overlap between the aneurysm cases with the highest 
HMGA2 expression  and  the  dissection  cases  with  a  lower  expression  but  the 
average  expression  in  aortic  dissection  was  over  20  times  higher  than  in  aortic 
aneurysms. 
In  summary  there  are  some  facets,  which  let  this  pathomechanism  seem 
questionable and therefore favour the other explanation for the HMGA2 upregulation: 
A reaction to the injury from the dissection. Indeed there is a form of EMT associated 
with  wound repair  and tissue regeneration, labelled as type 2 EMT, during which 
fibroblasts are generated in order to reconstruct the tissue142.  In keratinocytes the 
process of wound re-epithelialisation is triggered by the transcription factor Slug, a 
mediator of EMT143. Even HMGA2 expression is linked to wound recovery: Chin and 
colleagues found a dramatic increase in  HMGA2 mRNA after balloon injury of rat 
carotid arteries, while Monzen et al. detected  HMGA2 re-expression in the mouse 
myocardium  after  myocardial  infarction144,  145.  It  therefore  seems  likely  that  the 
increase  in  HMGA2 expression  in  acute  aortic  dissection  and  the  accompanying 
EndMT  can  be  attributed  to  the  tearing  of  the  aorta  and  the  following  tissue 
regeneration. 
As a further result of this study the  let-7d expression of 17 acute aortic dissection 
tissue samples was quantified and compared to the HMGA2 expression in the same 
samples. There was no significant correlation between the two data sets, indicating 
that  let-7d does not regulate  HMGA2 in these cases of aortic dissection, otherwise 
one would expect a negative correlation. The miRNAs of the let-7 family are known to 
repress HMGA2 expression, a mechanism which is obliterated in some cancers146, 147. 
In hepatocellular carcinoma cell lines let-7g regulates EMT by repression of HMGA2 
and  K-Ras148.  Another  let-7  variant  might  be  responsible  for  the  repression  of 
HMGA2 in aortic dissection too or alternatively the missing regulation might be the 
reason for the HMGA2 upregulation.
The average HMGA2 expression in this study was thrice as high in women with acute 
aortic dissection as in men with the disease, which might be explained by the fact 
that the women were also significantly older. This coincides with a report of women 
being  significantly  older  when  suffering  from  aortic  dissection  than  men149.  The 
women  also  displayed  significantly  higher  in-hospital  mortality  than  men  and  an 
altered spectrum of symptoms.
Further studies about the upregulation of HMGA2 and the EndMT in aortic dissection 
should focus on the question whether these events are cause or consequence of the 
disease. A suitable approach to verify this problem would be the generation of a 
transgenic  mouse  model.  A  mouse  overexpressing  HMGA2 in  the  vascular 
endothelium could be generated by coupling HMGA2 with the Tie-2 promotor, which 
causes endothelium-specific gene expression as demonstrated in various mice150, 151. 
The mice generated this way should develop acute aortic dissections if HMGA2 is 
part of the aortic dissection pathogenesis.
Additionally  the  HMGA2 expression  in  whole  blood  samples  from  acute  aortic 
dissection cases and control samples should be quantified. The possibility to detect  
HMGA2 mRNA in blood samples has already been demonstrated in the peripheral 
blood of breast cancer patients152. This could be important since a reliable biomarker 
for acute aortic dissection is still lacking153. Aortic dissection is rare and sometimes 
accompanied by atypical symptoms, which results in a delay of diagnosis of the life-
threatening disease154. To aid the diagnosis a variety of blood based biomarkers have 
been proposed, such as D-dimers, soluble Elastin fragments, serum smooth muscle 
Myosin heavy chain or Calponin but none of them is completely reliable155-159. The 
increased  HMGA2 expression  in  aortic  dissection  suggests  a  possible  role  as  a 
biomarker for the mRNA, which could be part of a blood based biomarker profile 
comprising several biomarkers for an increased sensitivity and specificity.
4.2  Spatial  differences in  eNOS protein  levels  between BAV and  
TAV aortas
The question about the pathological mechanism leading to the development of aortic 
aneurysm  in  BAV  has  provoked  a  lot  of  controversy.  Two  main  theories  are 
discussed: One assumes a common congenital defect, which is responsible for the 
development  of  the  BAV and the  weakening of  the  aortic  wall;  the  other  deems 
hemodynamic changes through the altered valve morphology to cause shear stress 
and  therefore  weaken  the  aortic  wall.  The  difference  is  not  only  of  scientific 
importance but has also influence on the health of many patients undergoing surgery 
for BAV related aneurysm, as these develop either from a diseased aortic wall  or 
from the malformed aortic valve and therefore the correct surgical treatment is still 
subject of discussion58, 160.
The first theory sees the same developmental defect leading to the development of 
BAV and the weakening of the aortic wall. This assumption seems reasonable, since 
the aortic valve and the ascending aorta share a common neuroectodermal origin 
and therefore a genetic defect could apply to both tissues161,  162. Additionally cystic 
medial  necrosis,  characterised  by  elastic  lamina  fragmentation,  loss  of  smooth 
muscle  cells  and  accumulation  of  mucoid  material,  is  found  not  only  in  BAV 
associated  aneurysms  but  also  in  many  forms  of  heritable  aneurysm  disease, 
suggesting a common defect115,  163. Furthermore different BAV types seem to stem 
from different genotypes and therefore represent different forms of the disease40. A 
different genetic background of the BAV types could explain the fact that the L-R type  
is associated with more severe aortic root dilatation at a younger age39. There are 
two other arguments which seem to disprove the hemodynamic theory and therefore 
strengthen the genetic theory. The first one focuses on the assumption that only a 
diseased  (stenotic  or  insufficient)  BAV  would  lead  to  significant  changes  in 
hemodynamic and therefore the observation of Nistri et al., who found 52 % of young 
men with clinically normal BAV to have enlarged aortic dimensions, contradicts the 
hemodynamic theory43.  The second argument is found in a study by Yasuda and 
colleagues, in which they demonstrated an ongoing increase in aortic diameter in a 
cohort  of  13  BAV  patients  undergoing  aortic  valve  replacement,  which  was 
comparable to BAV patients without aortic valve replacement164. These data indicate 
a progression of aortic dilatation even after the aortic valve, which would cause the 
altered hemodynamic, was replaced and consequently speak for the genetic nature 
of BAV aortopathy. 
The second theory about the pathogenesis of aortic aneurysms related to BAV holds 
changes  in  hemodynamic  caused  by  the  deformed  aortic  valve  for  responsible. 
These alterations would cause abnormal shear stress on some areas of the aortic 
wall  and  thereby  weaken  the  aorta.  This  theory  is  supported  by  several  recent  
studies,  which  confirmed  an  abnormal  blood  flow  pattern  and  an  asymmetric 
distribution  of  shear  stress  in  patients  with  BAV  either  by  the  use  of  magnetic 
resonance imaging or by computational analysis165-169. Moreover different BAV types 
induced different flow patterns, which might also explain the association of the L-R 
BAV type to more severe aortic dilatation39, 168. Further evidence comes from studies 
analysing  apoptosis  and extracellular  matrix  remodelling  in  different  areas  of  the 
aorta.  Della  Corte  and  colleagues  demonstrated  asymmetric  changes  in  medial 
necrosis, extracellular matrix protein expression and smooth muscle cell apoptosis in 
BAV aneurysm compared to controls, with the convexity of the aorta more severe 
affected in most cases61,  62. Mohamed et al. confirmed that inhibition of Caspase 3 
protects vascular smooth muscle cells significantly more from apoptosis if they are 
derived from the BAV concavity than from the BAV convexity170.  The same group 
detected asymmetric  protein expression of  matrix metalloproteinases (MMPs) and 
tissue  inhibitor  of  matrix  metalloproteinase  (TIMPs),  two  proteins  involved  in 
extracellular  matrix  remodelling171.  Taken  together  these  studies  indicate  an 
abnormal hemodynamic in BAV, which may result in smooth muscle cell apoptosis 
and extracellular matrix remodelling, which in turn seems to be more severe at the 
convexity of the aorta than at the concavity. Additionally the two arguments outlined 
above, which seemingly disproved the hemodynamic theory, have been challenged 
by recent literature. Two studies seem to prove that the clinically normal BAV does 
produce  an  abnormal  hemodynamic,  which  nullifies  the  argument  that  a  high 
prevalence of aneurysms in patients with normal BAV supports the genetic theory168, 
172. The progression in aortic dilatation after aortic valve replacement demonstrated 
by Yasuda and colleagues has been questioned by a recent study of Charitos et al.,  
who  did  not  detect  a  significant  increase  in  aortic  diameter  after  aortic  valve 
replacement in a cohort of 360 BAV patients compared to the general population173. 
Many of these recent observations seem to support the hemodynamic theory better  
than  the  genetic  theory,  although  the  extensive  amount  of  extracellular  matrix 
remodelling and gene expression changes found at certain aortic sites in BAV seems 
to suggest further mechanisms besides simple shear stress to be involved. 
As a part of this study the expression of the eNOS protein was quantified at four 
different sites of the aorta in BAV and TAV patients suffering from aortic aneurysms. 
The spatial distribution of the eNOS protein within the aorta proved to be different  
between BAV and TAV patients,  with the eNOS amount being higher in the BAV 
concavity  and  significantly  lower  in  the  BAV  proximal  aorta  than  in  its  TAV 
counterpart. The eNOS protein expression was significantly higher in the concavity 
than  in  the  proximal  aneurysm  and  the  convexity  of  BAV  patients,  while  the 
differences in TAV aortic areas where not significant. These results suggest a spatial  
dysregulation of eNOS expression in BAV when compared to TAV. 
The eNOS is an enzyme which produces nitric oxide (NO), a messenger molecule of 
the  vascular  system  with  manifold  influence  on  vascular  homeostasis.  The  NO 
produced by eNOS causes relaxation of the vessel  wall  through activation of the 
soluble  guanylate  cyclase174,  175.  The  NO molecule  is  also  able  to  regulate  gene 
expression and the translation of mRNA and therefore influence cellular activity176-178. 
Furthermore expression and activity of the eNOS are known to be upregulated by the 
influence of fluid shear stress on endothelial cells179, 180.
Therefore the spatial differences in eNOS protein expression between BAV and TAV 
suggest a role for the enzyme in shear stress induced BAV aortopathy.  It  seems 
probable  that  the  asymmetric  hemodynamic  in  BAV  would  lead  to  an  irregular 
distribution  of  shear  stress  around the  aorta.  This  would  give  rise  to  the  spatial  
dysregulation of eNOS expression seen in the results of this study,  which in turn 
would  provoke an imbalance of  NO distribution  in  the  different  aortic  areas.  The 
resulting changes in gene expression and mRNA translation could be sufficient to 
explain  the  asymmetric  extracellular  matrix  remodelling  and  smooth  muscle  cell  
apoptosis observed in BAV-related aneurysms and therefore present an additional 
mechanism  involved  in  the  development  of  ascending  aortic  aneurysm  in  BAV 
disease. 
The  NO  released  to  the  vasculature  can  modify  the  apoptotic  behaviour  of  the 
surrounding cells, as it directly inhibits caspases113. In an animal model mice deficient 
of  eNOS  displayed  increased  cardiomyocyte  apoptosis  and  caspase  3  activity,  
suggesting an anti-apoptotic effect of  the NO produced by eNOS181.  In fact basal 
levels of NO seem to protect from apoptosis, while high NO concentration can act  
pro-apoptotic182. These properties of NO seem relevant, since the loss of vascular 
smooth  muscle  cells,  detected  during  cystic  medial  necrosis  in  BAV aortopathy, 
stems  from  apoptosis114.  Interestingly  the  BAV  convexity,  which  is  more  severe 
affected  by  cystic  medial  necrosis  according  to  della  Corte  et  al.61,  displayed  a 
significantly decreased eNOS expression compared to the concavity in the results of 
this study. 
To further verify the effect of NO on aortic cell apoptosis, aortic endothelial cells and 
vascular smooth muscle cells, the two main cell types of the aorta, were subject to  
the inhibition of  NO synthesis.  Afterwards  the  expression  of  35  apoptosis-related 
proteins was evaluated with a proteome profiler array.  In vascular smooth muscle 
cells the cytosolic  level  of  the serine protease HTRA2/Omi increased significantly 
after inhibition of NO synthesis,  in aortic endothelial  cells the cytosolic amount of  
Cytochrome c increased, albeit the difference was not significant with p = 0.069. Both 
proteins are released from the mitochondria as a consequence of the induction of the 
intrinsic  apoptosis  pathway  and  elicit  apoptosis  once  being  present  in  the 
cytoplasm116,  117. Therefore NO in the aorta seems to inhibit the intrinsic apoptosis 
pathway,  a  mechanism which  could  be  disturbed  by  the  spatial  dysregulation  of 
eNOS. Consequentially the differences in eNOS protein expression in certain areas 
of the BAV aorta could lead to the diminishment of apoptosis protection in these 
areas and an increase in cystic  medial  necrosis,  which would facilitate aneurysm 
development.
The results of the latter part of this study are of limited value, because the level of NO 
inhibition is not correlated to the decrease in eNOS expression and therefore does 
not  necessarily represent  the  in  vivo condition. Continuative studies should try to 
mimic the interactions between hemodynamic, eNOS expression and anti-apoptotic 
influence of NO. Commercially available flow chambers can simulate shear stress on 
cells by creating circular flow of cell medium and could be used to expose aortic cells 
to different degrees of shear stress, like normal shear stress (as in TAV), increased 
shear  stress  or  decreased  shear  stress.  The  expression  of  eNOS  and  the 
concomitant NO production should be quantified for the various degrees of shear 
stress. Afterwards apoptosis could be induced in these cells, with calcium chloride for 
instance, and the susceptibility of the cells to apoptosis as well the exact apoptotic  
pathways  should  be determined  to  verify  the  relation  between  asymmetric  shear 
stress and aortic cell apoptosis.
4.3 Differences in microRNA 208a expression over the course of  
atrial fibrillation
The expression of the miRNA 208a was quantified in left atrial appendage tissue of 
patients with atrial fibrillation during this study. The data was grouped according to 
the  duration  of  the  arrhythmia  and  the  miRNA  208a  expression  was  compared 
between paroxysmal,  persistent  and long-standing persistent  atrial  fibrillation. The 
miRNA expression was lower in paroxysmal than in persistent atrial fibrillation but the 
difference was not significant. The expression in long-standing persistent arrhythmias 
was even lower than in paroxysmal atrial fibrillation and significantly lower than in  
persistent atrial fibrillation with a p value of 0.02, which indicates a decline in miRNA 
208a  expression  over  time  from  persistent  to  long-standing  persistent  atrial 
fibrillation. 
The miRNA 208a is part of the miRNA 208 family, comprising also miRNA 208b and 
miRNA 499. Those three miRNAs are located intronic to the myosin heavy chain 
genes Myh6, Myh7 and Myh7b and are coexpressed with them. The miRNA 208a is 
located within  Myh6 coding for the fast  myosin heavy chain (MHC), while miRNA 
208b and miRNA 499 are encoded within Myh7 and Myh7b, respectively, coding for 
slow  MHC isoforms123. In healthy human adult atrium the  MHC is the dominant 
myosin heavy chain form183, whereas cardiovascular disease is often accompanied 
by a switch to  MHC. A decrease in fast  MHC is reported in human heart failure, 
leading to a decline of cardiac contractility184, 185. The shift from fast  MHC to slow  
MHC is also reported from chronic or permanent atrial fibrillation and is assumed to 
contribute  to  the  contractile  dysfunction,  which  arises  with  longer  lasting 
arrhythmias186-188. This loss of contractility seemingly facilitates the sustaining of the 
arrhythmia together with electrical and structural remodelling of the atria189. 
So the decline in miRNA 208a expression seems to be a by-product of the decrease 
in  MHC it is coexpressed with. Therefore the question remains whether the change 
in miRNA 208a expression does contribute to the sustaining of the arrhythmia by 
itself,  or  if  the  ongoing  atrial  fibrillation  can  be  attributed  solely  to  the  switch  in 
dominant MHC isoforms.
In a study by Callis and colleagues mice with transgenic overexpression of miRNA 
208a, as well as mice lacking the micro RNA, displayed arrhythmias and failure in  
cardiac  conduction,  indicating  a  role  for  miRNA  208a  in  atrial  fibrillation 96. 
Interestingly the same study reported miRNA 208a to be required for the expression 
of  the  gap  junction  protein  Connexin  40,  which  seems  to  be  decreased  and 
distributed more laterally in sustained human atrial fibrillation190-192. Thus a decline of 
miRNA  208a  expression  with  the  ongoing  arrhythmia  could  lead  to  a  loss  of 
Connexin  40  in  the  atrium,  thereby  altering  conduction  and  sustaining  the  atrial 
fibrillation.
One important question not resolved by the results of this study is whether there is a  
difference  in  miRNA 208a  expression  between  patients  with  atrial  fibrillation  and 
healthy controls. The group around Slagsvold et al. just very recently addressed this 
question  in  a  study about  miRNA in  atrial  fibrillation.  They used an array  based 
approach to quantify the expression of all human miRNAs presented in the miRBASE 
16.0  build193.  Remarkably  miRNA  208a  was  the  only  miRNA  significantly 
downregulated in  left  and right  atrium of  atrial  fibrillation compared to  patients in 
sinus rhythm, thereby highlighting its importance in atrial fibrillation. A simultaneously 
published study by the same group compared expression of miRNA between the left 
and the right atrium of atrial fibrillation patients. Again miRNA 208a was one of the  
few  miRNA  differently  regulated  between  the  atria,  with  a  significantly  higher 
expression  in  the  left  atrium194.  The  patient  collective  in  both  studies  comprised 
almost equally paroxysmal and chronic atrial fibrillation, which makes it is feasible  
that the difference in miRNA 208a expression between atrial  fibrillation and sinus 
rhythm controls  was caused by the decline in  the miRNA in  patients with  longer 
lasting arrhythmias.
Further research on the subject should try to establish miRNA 208a as a blood-based 
biomarker for atrial fibrillation and therefore determine the expression of the miRNA 
in blood or serum of patients and controls. Many miRNAs, including miRNA 208a, 
can be detected in blood where they are either bound to proteins or enveloped in 
small  membraneous particles like exosomes195,  196.  In a recent study miRNA 208a 
was  confirmed as a  highly  sensitive  and specific  biomarker  for  acute  myocardial  
infarction, emphasising its usefulness as a blood-based marker197. The results of this 
study suggest a decrease of miRNA 208a expression over the course of ongoing 
atrial fibrillation, thus the miRNA could not only be used to detect the arrhythmia but 
also to discriminate between different durations of atrial fibrillation.
5. Summary
The results  of  three studies  about  gene expression  differences in  cardiovascular 
disease are presented within this thesis.
The first topic covers the involvement of the HMGA2 gene in cellular processes found 
in acute aortic dissection, a disease characterised by the splitting of the aortic layers 
leading  to  a  high  mortality.  Many  forms  of  aortic  dissection  disease  have  a 
dysregulation of the TGF- pathway in common, a signalling pathway, which is linked 
to HMGA2 induced epithelial  to mesenchymal transition (EMT) in cancer. Since it 
seems  probable  that  such  a  relation  also  exists  in  acute  aortic  dissection,  the 
expression of the  HMGA2 gene was quantified in 19 samples of ascending aortic 
dissection  tissue  and  32  samples  of  other  cardiovascular  disease.  Indeed  aortic 
tissue  of  acute  aortic  dissection  samples  revealed  a  significantly  higher  HMGA2 
expression than aortic tissue of the other cardiovascular disease samples. Further on 
the HMGA2 protein was detected together with several markers of EMT in the aortic 
endothelium surrounding the vasa vasorum. These results suggest the upregulation 
of  HMGA2  in  the  endothelium  of  aortic  dissection  tissue,  accompanied  by  the 
transition of these endothelial cells to mesenchymal cells, a variant of EMT termed 
endothelial  to  mesenchymal  transition  (EndMT).  It  is  not  clear  if  this  mechanism 
contributes to the pathogenesis of acute aortic dissection by weakening of the aortic 
endothelium, or if the EndMT is a reaction to the injury.
The second study focuses on differences of  the  spatial  distribution  of  the eNOS 
protein within the aorta of patients with bicuspid aortic valve (BAV). The BAV is a 
common congenital  defect of only two aortic valve leaflets compared to the three 
leaflets  of  a  normal  tricuspid  aortic  valve  (TAV).  The  disease  is  associated  with 
aneurysms and dissections of the ascending aorta, possibly generated by irregular 
hemodynamic and aortic wall shear stress through the malformed aortic valve. The 
amount of the eNOS protein was quantified in four different aortic sites of 14 aortic  
aneurysm  patients  with  BAV  and  5  with  TAV.  The  eNOS  protein  level  differed 
significantly between aortic areas in BAV, while the differences in TAV where not 
significant.  Additionally  the  BAV  proximal  aorta  featured  significantly  less  eNOS 
protein than the corresponding area in TAV. A spatial  dysregulation of the eNOS 
expression in BAV is implied by these data, probably caused by changes in shear 
stress, which is known to regulate eNOS gene expression and protein activity. The 
nitric oxide produced by eNOS has an anti-apoptotic effect on the surrounding tissue 
and therefore the amounts of 35 apoptosis-related proteins were quantified with a 
proteome profiler array after inhibition of nitric oxide synthesis in cultured aortic cells.  
The cytosolic level of the pro-apoptotic serine protease HTRA2/Omi proved to be 
significantly increased after inhibition of nitric oxide synthesis. Since this protein is 
normally released from the mitochondria into the cytosol during the intrinsic apoptosis 
pathway, the nitric oxide produced by eNOS seems to have an inhibitory effect on the 
intrinsic apoptosis pathway. The results of this study indicate the spatial dyregulation 
of  the  eNOS protein  in  BAV,  probably  due to  an  altered hemodynamic,  and the 
associated irregular nitric oxide distribution. A loss of the anti-apoptotic properties of  
nitric  oxide  could  give  raise  to  aortic  cell  apoptosis  in  certain  aortic  areas,  a 
mechanism known to contribute to the pathogenesis of aneurysm and dissections in 
BAV.
The miRNA 208a was quantified in tissue of atrial  fibrillation patients in  the third 
study. Atrial fibrillation is the most common form of cardiac arrhythmia and bears an 
increased risk of stroke. Ongoing atrial fibrillation can sustain itself by electrical and 
structural  remodelling  of  the  atria  and  therefore  it  is  classified  according  to  the 
duration of the arrhythmia. The cardiac specific miRNA 208a was quantified in left 
atrial appendage tissue of 2 patients with paroxysmal atrial fibrillation, 10 patients 
with  persistent  and  7  patients  with  long-standing  persistent  atrial  fibrillation.  The 
miRNA  expression  was  significantly  decreased  in  long-standing  persistent  atrial 
fibrillation  compared  to  persistent  atrial  fibrillation,  suggesting  a  decline  over  the 
course of the arrhythmia. The miRNA 208a is co-expressed with the  Myh 6 gene, 
coding for the fast  myosin heavy chain. A switch from fast  myosin heavy chain to 
slow   myosin heavy chain is known in atrial fibrillation and the decline in miRNA 
208a might be a by-product of this alteration. Alternatively the change in miRNA 208a 
expression  might  contribute  to  sustaining  of  atrial  fibrillation,  since  studies  with 
transgenic  mice  suggest  a  role  for  the  miRNA  in  cardiac  conduction  and 
arrhythmogenesis.
6. Zusammenfassung
Die  Ergebnisse  von  drei  Studien  über  Genexpressionsunterschiede  in 
kardiovaskulären Erkrankungen werden in dieser Doktorarbeit präsentiert. 
Die erste Studie umfasst die Beteiligung des HMGA2 Gens an zellulären Prozessen, 
die während einer akuten Dissektion der Aorta auftreten, einer Erkrankung, die durch 
einen  Riss  zwischen  den  Aortenschichten  und  einer  damit  verbundene  hohe 
Sterblichkeitsrate  charakterisiert  wird.  Viele  Formen  der  akuten  Aortendissektion 
haben  eine  Dysregulierung  des  TGF- Signalweges  gemeinsam,  einen 
Signaltransduktionsweg,  der  mit  der  HMGA2  induzierten  epithelialen-
mesenchymalen Transition (EMT) in Krebserkrankungen in Verbindung steht. Da es 
möglich erscheint, dass eine solche Verbindung auch in akuten Aortendissektionen 
existiert, wurde die  HMGA2 Expression in 19 Gewebeproben von Dissektionen der 
aufsteigenden Aorta und 32 Gewebeproben anderer kardiovaskulärer Erkrankungen 
quantifiziert. Gewebeproben von akuten Aortendissektionen wiesen in der Tat eine 
signifikant  höhere  HMGA2 Expression  als  die  Aortengewebeproben  von  anderen 
kardiovaskulären  Erkrankungen  auf.  Weiterhin  wurde  das  HMGA2  Protein 
zusammen  mit  verschiedenen  EMT-Markerproteinen  in  den  die  Vasa  vasorum 
umgebenen Endothelzellen detektiert.  Diese Ergebnisse deuten auf die vermehrte 
Expression des HMGA2 Proteins im Endothel von Aortendissektionsgewebe und die 
gleichzeitige  Transition  dieser  Endothelzellen  zu  mesenchymalen  Zelle  hin,  eine 
EMT  Variante,  die  als  endotheliale-mesenchymale  Transition  bezeichnet  wird 
(EndMT).  Es  ist  nicht  klar,  ob  dieser  Mechanismus  durch  die  Schwächung  des 
Aortenendothels zur Pathogenese der akuten Aortendissektion beiträgt oder ob er 
eine Reaktion auf die enstandene Verletzung ist. 
Die  zweite  Studie  hat  die  Unterschiede  in  der  räumlichen  Verteilung  des  eNOS 
Proteins  innerhalb  der  aufsteigenden  Aorta  von  Patienten  mit  bikuspider 
Aortenklappe  (BAV)  zum  Thema.  Die  BAV  ist  ein  häufig  auftretender,  erblicher 
Defekt,  der,  im  Gegensatz  zur  normalen  trikuspiden  Aortenklappe  (TAV),  die 
Ausbildung  von  nur  zwei  Aortenklappensegeln  zur  Folge  hat.  Die  Erkrankung 
begünstigt  die  Enstehung  von  Aortenaneurysmen  und  Aortendissektionen, 
möglicherweise  durch eine veränderte Hämodynamik  und veränderte Scherkräfte, 
die durch die deformierte Aortenklappe hervorgerufen werden.  Das eNOS Protein 
wurde an vier verschiedenen Stellen innerhalb der Aorta von 14 Aneurysmapatienten 
mit BAV und 5 Aneurysmapatienten mit TAV quantifiziert. Die eNOS Proteinmenge 
unterschied  sich  signifikant  zwischen  verschiedenen  Aortenbereichen  in  BAV, 
wohingegen die  Unterschiede in  TAV nicht  signifikant  waren.  Zusätzlich wies  die 
proximale  Aorta  von  BAV  Patienten  signifikant  weniger  eNOS  auf  als  das  TAV 
Gegenstück.  Diese Ergebnisse implizieren die räumliche Dysregulation der eNOS 
Expression  in  BAV,  die  wahrscheinlich  durch  die  Veränderung  der  Scherkräfte 
hervorgerufen  wird,  ein  Mechanismus  der  bekanntermaßen  die  eNOS 
Genexpression  und  Proteinaktivität  reguliert.  Das  von  eNOS  produzierte 
Stickstoffmonoxid hat einen anti-apoptotischen Effekt auf das umliegende Gewebe, 
weswegen die Mengen von 35 Apoptose Proteinen mit Hilfe eines Proteome Profiler 
Arrays quantifiziert  wurden, nachdem die Stichstoffmonoxidsynthese in kultivierten 
Aortenzellen  inhibiert  wurde.  Danach  war  die  cytosolische  Menge  der  pro-
apoptotischen  Serinprotease  HTRA2/Omi  signifikant  erhöht.  Da  das  Protein 
normalerweise  während  des  intrinschen  Apoptosesignalweges  aus  den 
Mitochondrien  in  das  Cytosol  entlassen  wird,  scheint  das  von  eNOS produzierte 
Stickstoffmonoxid einen inhibitorischen Effekt auf die intrinsiche Apoptose zu haben. 
Zusammengefasst  deuten  die  Resultate  dieser  Studie  auf  die  räumliche 
Dysregulation  des  eNOS  Proteins  in  BAV  hin,  welche  wahrscheinlich  durch  die 
veränderte  Hämodynamik  hervorgerufen  wird  und  eine  unregelmäßige  Verteilung 
des  Stickstoffmonoxids  innerhalb  der  Aorta  bewirkt.  Der  Verlust  der  anti-
apoptotischen Eigenschaften  des Stichstoffmonoxids  in  betsimmten Aortenarealen 
könnte die Apoptose von Aortenwandzellen zur Folge haben, ein Mechanismus, der 
erwiesenermaßen zur Pathogenese von Aneurysmen und Aortendissektionen in BAV 
beiträgt.
In der dritten Studie wurde die Expression der miRNA 208a in Gewebe von Patienten 
mit  Vorhofflimmern quantifiziert.  Das Vorhofflimmern stellt  die  häufigste Form der 
kardialen Arrhythmie dar und ist mit einem erhöhten Schlaganfallrisiko verbunden. 
Anhaltenes Vorhofflimmern kann sich selbst durch die elektrische und strukturelle 
Umgestaltung der Vorhöfe aufrechterhalten, weswegen die Krankheit entsprechend 
ihrer Dauer klassifiziert wird. Die herzspezifische miRNA 208a wurde in Gewebe vom 
linken Herzohr von 2 Patienten mit paroxysmalen, 10 Patienten mit persistierenden 
und 7 Patienten mit lang anhaltendend persistierenden Vorhofflimmern quantifiziert. 
Die  miRNA  Expression  war  in  Gewebe  von  lang  anhaltend  persistierendem 
Vorhofflimmern, im Vergleich zu persitierenden Vorhofflimmer, signifikant erniedrigt,  
was einen Rückgang über den Verlauf der Arrhythmie nagelegt. Die miRNA 208a 
wird mit dem Myh6 Gen koexprimiert, welches die schnelle  Isoform der schweren 
Myosinkette  kodiert.  Es  ist  bekannt,  dass  bei  anhaltendem  Vorhofflimmern  das 
Umschalten von der Expression des schnellen  Myosins auf die langsame  Isoform 
erfolgt und der Rückgang der miRNA 208a Expression könnte nur ein Nebenprodukt  
dieses Ereignisses sein. Andereseits könnte miRNA 208a auch von bedeutung für 
die Pathogenese des Vorhofflimmerns sein, da Studien mit transgenen Mäusen auf 
eine Funktion der miRNA in der Reizleitung des Herzens und der Arrhythmogenese 
hindeuten.
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8. Abbreviations
°C Degree Celcius
MHC Alpha myosin heavy chain
MHC Beta myosin heavy chain
CT Delta delta cycle threshold
µg Microgram
µl Microlitre
µm Micrometer
A Adenine
AAD Acute aortic dissection
ACTA2 Alpha actin 2
ACTB Beta actin
AF Atrial fibrillation
aHTN Aterial hypertension
ANOVA Analysis of variance
AoV Aortic valve
BAV Bicuspid aortic valve
Bax BCL2-associated X protein
BCA Bicinchoninic acid
Bcl2 B-cell CLL/lymphoma 2
BMI Body mass index
BSA Bovine serum albumin
C Cytosine
C. elegans Caenorhabditis elegans
Ca2+ Calcium ion
CACNA1C Calcium channel, voltage-
dependent, L type, alpha 1C 
subunit
CACNB1 Calcium channel, voltage-
dependent, beta 1 subunit
CAD Coronary arterial disease
CD-34 CD34 molecule
cDNA Complementary DNA
CDKN1A cyclin-dependent kinase 
inhibitor 1A
CHADS2 Congestive heart failure/ 
hypertension/ age/ diabetes 
mellitus/ stroke
CHF Chronic heart failure
cm2 Square centimetre
CO2 Carbon dioxide
CRP C-reactive protein
DAPI 4',6-diamidino-2-phenylindole
DM Diabetes Mellitus
DNA Deoxyribonucleic acid
EMT Epithelial to mesenchymal 
transition
EndMT Endothelial to mesenchymal 
transition
eNOS Endothelial nitric oxide 
synthase
ESC European Society of 
Cardiology
et al. et alii
f Female
FADD Fas-associated via death 
domain
FAM 6-carboxyfluorescein
FCS Fetal calve serum
G Guanine
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase
GATA5 GATA binding protein 5
GJA1 Gap junction protein, alpha 1
H Hour
H&E Hematoxylin and eosin stain
HAEC Human aortic endothelial cells
HCl Hydrogen chloride
HIF-1a Hypoxia-inducible factor 1 
alpha
HMGA2 High mobility group AT-hook 2
HMOX1/HO-1 Heme oxygenase 1
HMOX2/HO-2 Heme oxygenase 2
Hoxa1 Homeobox A1
HSP Heat shock protein
HTRA2/Omi HtrA serine peptidase 2
ICa Inward C-type Ca2+ current
IgG-AP Immunoglobulin G with 
alkaline phosphatase
iNOS Inducible nitric oxide synthase
KCNJ2 Potassium inwardly-rectifying 
channel, subfamily J, member 
2
KCNN3 Potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 
3
kg Kilogram
K-Ras Kirsten rat sarcoma viral 
oncogene homolog
LA-D Left atrium diameter
Let-7 Lethal-7
L-NAME Nω-Nitro-L-arginine methyl 
ester hydrochloride
LV-EF Left ventricle ejection fraction
m Metre
M Molar
m2 Square metre
mg Milligram
MgCl2 Magnesium chloride
Min Minute
miRNA Micro RNA
MKI-67 Marker of proliferation Ki-67
ml Millilitre
mM Millimolar
mm Millimetre
M-MLV Moloney murine leukemia 
virus
MMP Matrix metalloproteinase
MRI Magnetic resonance imaging
mRNA Messenger RNA
MS Marfan syndrome
MV Mitral valve
MYH11 Myosin, heavy chain 11
Myh6 Myosin, heavy chain 6
Myh7 Myosin, heavy chain 7
Myh7b Myosin heavy chain 7b
NaCl Sodium chloride
NBT/BCIP Nitro blue tetrazolium/ 5-
Bromo-4-chloro-3-indolyl 
phosphate
ng Nanogram
Nkx2-5 NK2 homeobox 5
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
NOS Nitric oxide synthase
NYHA New York Heart Association
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDIA2 Protein disulfide isomerase 
family A, member 2
pH Potentia hydrogenii
PITX2 Paired-like homeodomain 2
PON2 Paraoxonase 2
R2 Coefficient of determination
RIPA Radioimmunoprecipitation 
assay
RNA Ribonucleic acid
RNU48 small nucleolar RNA, C/D box 
48
RNU6B RNA, U6 small nuclear 6
rRNA Ribosomal RNA
RT-PCR Reverse transcription PCR
SD Standard deviation
SDS-PAGE Sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis
sec Second
SNAI1 Snail family zinc finger 1
SNP Single nucleotide 
polymorphism
snRNA Small nuclear RNA
SPSS Statistical package for the 
social sciences
STJ Sinotubular junction
SV40 Simiam virus 40
T Thymine
TAA Thoracic aortic aneurysm
TAV Tricuspid aortic valve
TBS-T Tis buffered saline –Tween 20
TGFbRII Transforming growth factor-
beta receptor type 2
TGF-/TGFB Transforming growth factor, 
beta 1
Tie-2 Tunica internal endothelial cell 
kinase 2
TIMP Tissue inhibitor of matrix 
metalloproteinases
TNF Tumor necrosis factor
TNFRSF1A Tumor necrosis factor receptor 
superfamily, member 1A
TNFSF6 TNF superfamily, member 6
TRAIL TNF-related apoptosis-
inducing ligand
TV Tricuspid valve
U Unit
UFD1L Ubiquitin fusion degradation 1 
like
UTR Untranslated region
V Volt
VD Vascular disease
vs Versus
VSMC Vascular smooth muscle cells
xg Standard gravity
XIAP X-linked inhibitor of apoptosis
ZFHX3 Zinc finger homeobox 3
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